Transimmune maintains close collaborations with leading academic centers in Europe and the United States that include specialized clinical institutions, translational and research centers of excellence. These provide us with the ability to access rapid prototyping, disease model systems and clinical expertise.
Researchers and physicians at Medical School of Dermatology have been among the pioneers of the extracorporeal photopheresis and transimmunization and maintain a strong position in that field. Transimmune works closely with the Professor Edelson’s lab to build on the previous decades of insight surrounding extracorporeal photopheresis.
As a founding member of the Life Sciences Group of the Fraunhofer-Gesellschaft, which now comprises six institutes and one research establishment, the Fraunhofer IBMT cooperates closely with its industrial customers as well as public and private customers in the business areas of laboratory technology, theranostics and medical engineering. The IBMT’s strategy is focused on the areas of biomedical/medical engineering (especially non-invasive and minimally invasive as well as miniaturized technologies), biotechnology, implants, cryotechnology, biobanks and stem cell research.
HS LifeSciences manages the investment fund QureInvest. HS LifeSciences supports management and the scientific founders with scientific, financial and strategic expertise. This enables a focused and cost efficient growth of the companies during preclinical stages after which an industrial partner is sought to co-develop the technology through the subsequent clinical phases.
QureInvest II Investments (SCA) SICAR
QureInvest is an entrepreneurial investment fund managed by HS LifeSciences committed to invest in early stage companies within the medical innovation sector. The portfolio currently consists of nine companies that are all held directly by QureInvest